primary endpoint

Type: Keyphrase
Name: primary endpoint
First reported Sep 22 2014 - Updated 1 hour ago - 3 reports

DBV Technologies announces primary endpoint met in VIPES, Viaskin Peanut's Phase 2b clinical trial in peanut allergy

Largest clinical trial in peanut allergy desensitization ever completed, VIPES meets primary endpoint with Viaskin Peanut at the 250 µg dose with safety profile confirmed and excellent patient compliance demonstratedBy Lloyd DunlapBAGNEUX, France—DBV ... [Published Drug Discovery News - 18 hours ago]
First reported Sep 22 2014 - Updated 5 hours ago - 2 reports

Amgen Seeks FDA Approval for Blinatumomab in ALL

Anthony S. Stein, MDA Biologics License Application has been submitted to the FDA for the bispecific T-cell engager (BiTE) antibody blinatumomab as a treatment for adult patients with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic ... [Published OncLive - 18 hours ago]
First reported 19 hours ago - Updated 19 hours ago - 1 reports

Mallinckrodt Pharmaceutical Rolls out MNK-155 Trial Data

Mallinckrodt recently reported that a Phase 3 efficacy trial ofinvestigational MNK-155 met the study's primary endpoint of improvedpain scores vs. placebo over the first 48 hours followingbunionectomy (pAccording to a company release, this difference ... [Published HighBeam Research - 19 hours ago]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

New Study Examines the Optimal Duration Time of Dual Antiplatelet Therapy in Patients With Second-generation Drug-eluting Stents

— According to a new study , patients receiving six months of dual antiplatelet therapy (DAPT) after receiving a second-generation drug-eluting stent (DES) appeared to have similar outcomes to patients who received DAPT for a full year. Findings were ... [Published Diagnostic & Invasive Cardiology - Sep 22 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Gilead's Phase II pancreatic cancer study fails to meet primary endpoint

Gilead Sciences, Inc., a research-based biopharmaceutical company, has announced results from a Phase II study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2, in combination with gemcitabine for patients with previously untreated ... [Published Individual.com - Sep 22 2014]
First reported Sep 21 2014 - Updated Sep 21 2014 - 1 reports

Novel single-pill HIV treatment may be on the way

the Clinical Advisor take:A single-pill treatment for the human immunodeficiency virus ( HIV ) proved less toxic than a regimen using separate drugs, according to research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy ... [Published The Clinical Advisor - Sep 21 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Study Evaluates Triple Therapy for Anticoagulation After Drug-Eluting Stenting

— A new study investigating different durations of triple therapy for anticoagulation after drug-eluting stent (DES) implantation demonstrated that six weeks of drug therapy was not superior to six months of therapy with regard to net clinical outcomes. ... [Published Diagnostic & Invasive Cardiology - Sep 19 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Novo Nordisk's Phase IIIb trial of Ryzodeg fails to meet primary endpoint

Novo Nordisk has reported results from a 26-week randomized multinational Phase IIIb trial, which showed that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus ... [Published PBR - News - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 19 2014 - 1 reports

Update: Oncolytics Announced Data From Phase II Study, Shares Plummeted

Summary Oncolytics announced overall and KRAS-mutated patient data from its Phase II pancreatic cancer study. In my original analysis I said that REOLYSIN is expected to work on some of the most prevalent forms of cancer. Although the study missed ... [Published Seeking Alpha - Sep 18 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Merck Halts Development of Lung Cancer Treatment

Merck said it is giving up on its cancer treatment candidate tecemotide as a monotherapy for stage III non-small cell lung cancer.The therapy already had failed a previous Phase III trial last fall, but Merck proceeded with development based on one ... [Published FDA News - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Lilly Cancer Treatment Reaches Primary Endpoint

A potential cancer treatment being developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) continues to move forward. The pharmaceutical maker reports a late-stage trial shows patients taking Cyramza in combination with another drug had a "statistically ... [Published Inside INdiana Business - Sep 18 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 3 reports

Intravascular ultrasound-guided intervention in patients with chronic total occlusion

A new study found that intravascular ultrasound (IVUS) -guided intervention in patients with chronic total occlusion (CTO) could improve outcomes compared to a conventional angiography-guided approach during percutaneous coronary intervention (PCI). The ... [Published Science Daily - Sep 17 2014]

Quotes

...high relapse rates and have limited treatment options," said Sean E Harper, M D , executive vice president of research and development at Amgen. "The filing for blinatumomab brings us a step closer to first realizing the potential of BiTE technology and represents our commitment to evaluating this novel approach in a broad range of difficult-to-treat cancers."
"A simple urine test which can detect the human papilloma virus HPV) could offer women a much less invasive alternative to [current] cervical cancer screening" The Independent reports
...Dr. Sharman commented, "We have been very pleased with the safety and activity profile of the combination seen thus far in our Phase 1/2 trial, and are excited to lead this important clinical trial. Combining a glycoengineered anti-CD20 monoclonal antibody with ibrutinib has the potential to materially increase the number of patients benefitting from treatment with ibrutinib therapy. The PhasePhase 2 trial has enrolled very quickly throughout our clinical research network with patients, physicians, and nurses recognizing the benefits of this study."
..." Dr. Gunn added, "SSIs represent a new approach to treating cancer and immune-related disease, such as Crohn's disease. Rather than blocking or disrupting a process in the body, SSIs aim to restore the body's normal immune response."

More Content

All (1232) | News (1031) | Reports (0) | Blogs (175) | Audio/Video (0) | Fact Sheets (1) | Press Releases (14)
sort by: Date | Relevance
Amgen Seeks Approval for Breakthrough Leukemia ... [Published Pharmacy Times - 1 hour ago]
Amgen seeks US FDA approval for investigational... [Published PharmaBiz - 5 hours ago]
HPV urine test could screen for cervical cancer [Published Eastbourne Herald - 9 hours ago]
TG Therapeutics Announces SPA Agreement With FD... [Published Drugs.com - 11 hours ago]
Qu Biologics Closes Oversubscribed Private Fund... [Published Individual.com - 11 hours ago]
Cryptogenic Stroke: Could It Be Undiagnosed Afib? [Published American Journal of Transplantation - 12 hours ago]
Amgen Seeks FDA Approval for Blinatumomab in ALL [Published OncLive - 18 hours ago]
DBV Technologies announces primary endpoint met... [Published Drug Discovery News - 18 hours ago]
Novo Nordisk Reveals Fresh Data on Xultophy for... [Published Yahoo! Finance - 19 hours ago]
Mallinckrodt Pharmaceutical Rolls out MNK-155 T... [Published HighBeam Research - 19 hours ago]
Amgen Submits FDA Application for Blinatumomab ... [Published PT Community - 19 hours ago]
Lilly Posts Positive Trial Results For Cyramza ... [Published Bioresearch Online - 21 hours ago]
Five things for pharma marketers to know: Monda... [Published Medical Marketing And Media - 23 hours ago]
TAVR Cerebral Protection Device Reduces Stroke ... [Published Diagnostic & Invasive Cardiology - 23 hours ago]
BRIEF-DBV Technologies says primary endpoint me... [Published Reuters UK - 23 hours ago]
DBV Technologies Announces Primary Endpoint Met... [Published GlobeNewswire: Acquisitions News - 23 hours ago]
Gilead Sciences: A Preview of Important HIV Dru... [Published TheStreet.com - 23 hours ago]
Gilead Sciences: A Preview of Important HIV Dru... [Published The Street Latest - Sep 22 2014]
DBV Technologies Announces Primary Endpoint Met... [Published BusinessWeek - Sep 22 2014]
Amgen submits Biologics License Application for... [Published Drug Discovery News - Sep 22 2014]
New Study Examines the Optimal Duration Time of... [Published Diagnostic & Invasive Cardiology - Sep 22 2014]
Alcobra completes all patient visits in Phase I... [Published Pharmaceutical Business Review - Sep 22 2014]
Amgen pushes for early FDA OK of leukemia drug ... [Published FierceBiotech - Sep 22 2014]
Amgen files 'breakthrough' leukaemia drug in th... [Published Pharma Times - Sep 22 2014]
POPE-2: Colchicine failed to reduce postoperati... [Published Orthopedics Today - Sep 22 2014]
OXiGENE enrolls first patient in Phase II GI-NE... [Published Individual.com - Sep 22 2014]
Amgen Submits BLA For Blinatumomab - Quick Facts [Published RTTNews.com - Sep 22 2014]
Amgen Submits Biologics License Application For... [Published Benzinga.com - Sep 22 2014]
Amgen Submits Biologics License Application for... [Published Scottrade - Sep 22 2014]
Sanofi’s dengue vaccine candidate completes eff... [Published Express Pharma - Sep 22 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Treatment as Onset can slow development of MS [Published Multiple Sclerosis Research - Sep 22 2014]
Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; for the TOPIC Study Group.  Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis(TOPIC): a randomised, ...
Novo Nordisk's Phase IIIb trial of Ryzodeg fail... [Published PBR - News - Sep 19 2014]
Novo Nordisk has reported results from a 26-week randomized multinational Phase IIIb trial, which showed that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus ...
Moberg Pharma Announces Successful Results for ... [Published Business Wire Health News - Sep 17 2014]
STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Pharma (STO:MOB) Moberg Pharma AB (OMX: MOB) announces successful top-line results from a phase II study for MOB-015 in onychomycosis (nail fungus). The primary endpoint, mycological cure after 15 months, ...
News from ACTRIMS/ECTRIMS 2014 Pharma in the hu... [Published Multiple Sclerosis Research - Sep 14 2014]
#MS research Pharma led #remyelination trials ongoing RR Wang, Y Chen, T Guo, W Zhen, TB Guo, RY Zhao,AA Liu1, JP Rubio, D Krull, J Lu, M Song, P Thompson,S Wang1, JC Richardson.Histamine H3 receptor negatively regulates oligodendrocyte differentiation ...
Lilly Announces CYRAMZA™ Phase III Second-Line ... [Published PR Newswire: Health - Sep 12 2014]
INDIANAPOLIS, Sept. 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA™) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
DBV Technologies Announces Primary Endpoint Met... [Published GlobeNewswire: Acquisitions News - 23 hours ago]
Moberg Pharma announces successful results for ... [Published GlobeNewswire: Acquisitions News - Sep 17 2014]
NeuroSearch appeals Copenhagen City Court judgm... [Published GlobeNewswire: Acquisitions News - Aug 18 2014]
Sanofi and Regeneron Announce Positive Results ... [Published GlobeNewswire: Acquisitions News - Jul 09 2014]
GSK and Genmab announce top-line results from a... [Published GlobeNewswire: Advertising News - Jun 27 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.